Recent investigations expose how artificial intelligence companies have established unprecedented access to Trump administration health officials, creating direct communication channels that bypass traditional regulatory oversight. This strategic positioning allows tech leaders to influence healthcare policy decisions and shape regulatory frameworks affecting the AI industry, raising concerns about potential conflicts of interest and the concentration of policy-making power among corporate stakeholders rather than public health advocates.

Summary auto-generated by AI from the original publisher's content. Editorial standards.